Recent IV-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: An open-label pilot study

Table 2 Sustained viralogical response by HCV genotype, gender and sex (wk 72), n (%)

All genotypes
< 800.000 IU/mL	23/33 (70)
≥ 800.000 IU/mL	13/25 (52)
Genotype 1
< 800.000 IU/mL	5/6 (83)
≥ 800.000 IU/mL	9/19 (47)
Non-genotype 1
< 800.000 IU/mL	18/27 (67)
≥ 800.000 IU/mL	4/6 (67)
Sex
Male	16/33 (49)
Female	14/25 (56)

Sixteen patients who failed to follow up, dropped off the study due to side effects or died and were taken as non-responders, n = 58.